Misonix (NASDAQ:MSON) was downgraded by investment analysts at ValuEngine from a “buy” rating to a “hold” rating in a research note issued on Friday.

A number of other research firms also recently weighed in on MSON. Canaccord Genuity started coverage on Misonix in a research report on Friday, August 24th. They issued a “buy” rating and a $24.00 target price for the company. TheStreet downgraded Misonix from a “c” rating to a “d+” rating in a research report on Friday, September 7th. Finally, Craig Hallum started coverage on Misonix in a research report on Tuesday, September 11th. They issued a “buy” rating and a $28.00 target price for the company.

MSON traded down $0.41 during trading on Friday, reaching $16.50. The stock had a trading volume of 10,900 shares, compared to its average volume of 17,333. Misonix has a 1-year low of $8.25 and a 1-year high of $21.43.

Misonix (NASDAQ:MSON) last released its earnings results on Thursday, November 8th. The medical equipment provider reported ($0.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.09). The firm had revenue of $9.36 million during the quarter. Misonix had a negative return on equity of 14.05% and a negative net margin of 23.24%.

In other news, VP Joseph J. Brennan sold 8,357 shares of the stock in a transaction on Thursday, December 6th. The stock was sold at an average price of $15.91, for a total transaction of $132,959.87. Following the completion of the sale, the vice president now owns 5,649 shares in the company, valued at approximately $89,875.59. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Christopher H. Wright sold 10,000 shares of the stock in a transaction on Wednesday, November 28th. The shares were sold at an average price of $16.31, for a total value of $163,100.00. Following the sale, the vice president now owns 10,000 shares of the company’s stock, valued at approximately $163,100. The disclosure for this sale can be found here. Insiders sold 18,958 shares of company stock valued at $305,838 over the last 90 days. 24.60% of the stock is currently owned by insiders.

Large investors have recently made changes to their positions in the company. Wells Fargo & Company MN lifted its position in shares of Misonix by 1,487.5% during the 3rd quarter. Wells Fargo & Company MN now owns 6,350 shares of the medical equipment provider’s stock valued at $117,000 after acquiring an additional 5,950 shares during the last quarter. Acadian Asset Management LLC lifted its position in shares of Misonix by 388.8% during the 3rd quarter. Acadian Asset Management LLC now owns 8,212 shares of the medical equipment provider’s stock valued at $152,000 after acquiring an additional 6,532 shares during the last quarter. Manatuck Hill Partners LLC acquired a new stake in shares of Misonix during the 3rd quarter valued at $329,000. BlackRock Inc. lifted its position in shares of Misonix by 39.0% during the 2nd quarter. BlackRock Inc. now owns 25,660 shares of the medical equipment provider’s stock valued at $318,000 after acquiring an additional 7,203 shares during the last quarter. Finally, Nordea Investment Management AB acquired a new stake in shares of Misonix during the 3rd quarter valued at $649,000. Institutional investors own 15.93% of the company’s stock.

About Misonix

Misonix, Inc, together with its subsidiaries, designs, develops, manufactures, and markets therapeutic ultrasonic medical devices in the United States, the Americas, Europe, Middle East, Asia Pacific, Africa, and internationally. The company offers BoneScalpel, an ultrasonic bone cutting and sculpting system for surgical procedures involving the precise cutting of bone while sparing soft tissue; SonaStar, a surgical aspirator that is used to emulsify and remove soft and hard tumors primarily in the neuro and general surgery field; and SonicOne, an ultrasonic cleansing and debridement system, which provides tissue specific debridement and cleansing of wounds and burns for the removal of devitalized tissue and fibrin deposits while sparing viable cells.

Featured Article: How Do You Calculate Return on Equity (ROE)?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Misonix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Misonix and related companies with MarketBeat.com's FREE daily email newsletter.